AAV gene therapy development and GMP manufacturing services

Gene Therapy Solutions

Gene therapies are revolutionizing treatment for genetic, neurological, ophthalmic, and rare diseases, but translating promising AAV programs into clinic-ready products is complex. ProBio's integrated Gene Therapy Solutions help sponsors accelerate development, de-risk manufacturing, and move confidently from discovery to the clinic.

Successful gene therapy development depends on reliable plasmid supply, efficient AAV production, and a seamless transition from discovery to clinical manufacturing. ProBio's integrated platform brings together proprietary PowerS™-ITRs plasmid technology, AAssistV™ plasmids, and the PowerS™-293 suspension cell line to enable high-quality AAV development and manufacturing.

With scalable production capabilities up to 200L and a global supply network, we help sponsors accelerate development, reduce risk, and advance programs with confidence.

AAV Discovery Services

Accelerate gene therapy research with AAV discovery services, including AAV packaging and pharmacology support for in vitro and in vivo evaluation of therapeutic candidates.

Learn More

High-Performance AAV Plasmids

Proprietary PowerS™-ITRs plasmid technology delivers <10% ITR recombination rates and yields up to 1 g/L for reliable AAV development.

Learn More

AAV Packaging & Feasibility Studies

Evaluate manufacturability early with CMC-enabling studies designed to reduce development risk and support process optimization.

Learn More

IND-Enabling AAV CMC

Integrated CMC solutions supporting delivery of GMP-grade AAV in as little as 8 months from DNA sequence.

Learn More

Clinical GMP AAV Manufacturing

Scalable GMP manufacturing with production capabilities up to 1,000L to support clinical development and beyond.

Learn More

From AAV Discovery to Commercial AAV Manufacturing

Accelerating Gene Therapies with ProBio

Integrated AAV gene therapy platform from discovery to GMP manufacturing

Integrated Development from Discovery to GMP

Accelerate AAV programs with a seamless pathway from discovery and packaging studies to IND-enabling CMC and GMP manufacturing. Our integrated approach reduces technology transfer risks and can deliver GMP-grade AAV in as little as 8 months from DNA sequence.

Proprietary AAV & Plasmid Technology Platforms

Leverage PowerS™-ITRrs, AAssistV™, and PowerS™-293 technologies designed to improve vector quality and manufacturing efficiency. PowerS™-ITRrs achieve <10% ITR recombination rates and plasmid yields of up to 1 g/L, while FDA DMF-ready platform components help streamline development.

Scalable AAV production with dual-site global manufacturing operations

Scalable Manufacturing with Global Supply Security

Support clinical development with high-yield AAV production and dual-site operations in the US and China. Our platform delivers crude titers up to 2E15 vg/L, recovery rates of 20-50%, and <10% empty capsids for reliable GMP manufacturing.